Research study for Crohn’s patients with perianal fistulas

IRB/UVA Tracking #
21358
Principal Investigator
Anne G Tuskey
Contact
Lakin Underwood
Contact Phone
434.243.6156
Official Trial Title
A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(
Study Description

The Division of Gastroenterology and Hepatology seeks adults, 18-75, with Crohn’s disease and perianal fistulas for a research study. The purpose of the study is to find out how well the study drug, Cx601, works compared to a placebo, including safety and tolerability, in patients with fistulizing Crohn’s Disease.

You may be eligible for this study if you have Crohn’s disease with fistulas and other treatments have not worked for you.

Study involves having an MRI 3 times over the course of the study, answering questions daily on an electronic device, and having the study drug placed in your fistula. There are at least 9 study visits, which may take between 2 and 5 hours, over 15 months.

All study-related insert exams, tests and experimental medication are provided free of charge.

Compensation

$125/visit